

# **Cannabinoid Receptor 2 (CB<sub>2</sub>) Signals via G-alpha-s and Induces IL-6 and IL-10 Cytokine Secretion in Human Primary Leukocytes**

Yurii Saroz<sup>1,2</sup>, Dan T. Kho<sup>2,3</sup>, Michelle Glass<sup>4</sup>, Euan Scott Graham<sup>2,3</sup>,

Natasha Lillia Grimsey<sup>1,2,\*</sup>

<sup>1</sup> Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland 1023, New Zealand

<sup>2</sup> Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand

<sup>3</sup> Department of Molecular Medicine and Pathology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand

<sup>4</sup> Department of Pharmacology and Toxicology, School of Biomedical Sciences, Division of Health Sciences, University of Otago, Dunedin, New Zealand

\* **Corresponding author:** n.grimsey@auckland.ac.nz, +64 9 923 1886.

## **Author ORCIDs:**

YS - <https://orcid.org/0000-0003-4699-3127>

DTK - <https://orcid.org/0000-0001-7193-2954>

MG - <https://orcid.org/0000-0002-5997-6898>

ESG – <https://orcid.org/0000-0002-2925-9126>

NLG - <https://orcid.org/0000-0003-3941-4537>

## Abstract


Cannabinoid receptor 2 (CB<sub>2</sub>) is a promising therapeutic target for immunological modulation. There is, however, a deficit of knowledge regarding CB<sub>2</sub> signaling and function in human primary immunocompetent cells. We applied an experimental paradigm which closely models the *in situ* state of human primary leukocytes (PBMC; peripheral blood mononuclear cells) to characterize activation of a number of signaling pathways in response to a CB<sub>2</sub>-selective ligand (HU308). We observed a “lag” phase of unchanged cAMP concentration prior to development of classically-expected G<sub>α<sub>i</sub></sub>-mediated inhibition of cAMP synthesis. Application of G protein inhibitors revealed that this apparent lag was a result of counteraction of G<sub>α<sub>i</sub></sub> effects by concurrent G<sub>α<sub>s</sub></sub> activation. Monitoring downstream signaling events, activation of p38 was mediated by G<sub>α<sub>i</sub></sub> whereas ERK1/2 and Akt phosphorylation were mediated by G<sub>α<sub>i</sub></sub>-coupled βγ. Activation of CREB integrated multiple components; G<sub>α<sub>s</sub></sub> and βγ mediated ~85% of the response, while ~15% was attributed to G<sub>α<sub>i</sub></sub>. Responses to HU308 had an important functional outcome – secretion of interleukins 6 (IL-6) and 10 (IL-10). IL-2, IL-4, IL-12, IL-13, IL-17A, MIP-1α, and TNF-α were unaffected. IL-6/IL-10 induction had a similar G protein coupling profile to CREB activation. All response potencies were consistent with that expected for HU308 acting via CB<sub>2</sub>. Additionally, signaling and functional effects were completely blocked by a CB<sub>2</sub>-selective inverse agonist, giving additional evidence for CB<sub>2</sub> involvement. This work expands the current paradigm regarding cannabinoid immunomodulation and reinforces the potential utility of CB<sub>2</sub> ligands as immunomodulatory therapeutics.

**Keywords:** cannabinoid receptor 2 (CB<sub>2</sub>), G protein-coupled receptor (GPCR), signaling, leukocytes, interleukin 6, interleukin 10

## Significance statement

Cannabinoid receptor 2 (CB2) is a G protein-coupled receptor which plays a complex role in immunomodulation and is a promising target in a range of disorders with immune system involvement. However, to date the majority of the studies in this field have been performed on cell lines, rodent models, or stimulated primary cells. Here we provide a detailed account of CB2-mediated signaling in primary human immune cells under conditions which closely mimic their *in vivo* state. We reveal a complex signaling system involving an unprecedented CB2 signaling pathway and leading to immunomodulatory functional outcomes. This work provides not only a critical foundation impacting CB2-targeted drug discovery, but reveals important wider considerations for GPCR signaling studies and model validity.

## Table of Contents Summary Figure



## Introduction

Cannabinoid Receptor 2 (CB<sub>2</sub>) is a class A G protein-coupled receptor (GPCR) which is expressed primarily in the immune system <sup>e.g. 1,2</sup> and is a promising therapeutic target for immune modulation in a wide range of disorders <sup>reviewed in 3</sup>. CB<sub>2</sub> couples to Gα<sub>i/o</sub> proteins inhibiting adenylyl cyclases <sup>e.g. 4,5</sup>, and limited evidence indicates coupling to Gα<sub>q</sub> <sup>e.g. 6</sup>. To date, there is no evidence for CB<sub>2</sub> coupling to Gα<sub>s</sub>; although increased cyclic adenosine monophosphate (cAMP) synthesis has been reported, this was coupled to Gα<sub>i/o</sub>, likely via Gβγ <sup>7,8</sup>. Downstream of G protein coupling, and perhaps involving modulation by β-arrestins <sup>9</sup>, activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) is a widely studied consequence of CB<sub>2</sub> activation reported in cell lines heterologously expressing this receptor <sup>e.g. 10</sup> and in rodent <sup>e.g. 11</sup> and human immunocompetent cell lines <sup>e.g. 8,12</sup>, with limited published evidence for such signaling in human primary leukocytes <sup>13,14</sup>. The paucity of studies on human primary leukocytes may in part be due to methodological difficulties such as low cell yields. Mitogenic or antigenic proliferative stimulations are widely used approaches to overcome some of these practical limitations <sup>e.g. 13,14</sup>. However, these methods cause lymphocytes to de-differentiate and turn into lymphoblasts – mitotically overactive cells – which do not closely model the *in situ* state of leukocytes <sup>15</sup>.

The limited literature regarding CB<sub>2</sub> signaling via other types of mitogen-activated protein kinases (MAPKs) indicates context-dependence of activation. CB<sub>2</sub> can induce p38 phosphorylation (p-p38) <sup>e.g. 16</sup>, which has been linked to growth inhibition of cancer cells, yet in LPS-stimulated monocytes p-p38 was decreased by a CB<sub>2</sub>-selective agonist <sup>12</sup>, while B lymphocytes <sup>17</sup> and dendritic cells <sup>18</sup> were non-responsive. Akt kinase (protein kinase B), an important mediator of immunomodulation <sup>reviewed in 19</sup> can be activated <sup>20</sup>, inhibited <sup>21</sup>, or unaffected <sup>22</sup> by CB<sub>2</sub> activation. A stress-activated protein kinase JNK (c-Jun NH2-terminal

kinase), involved in pro-inflammatory signaling <sup>reviewed in 23</sup>, has been shown to be activated <sup>24,25</sup> and inhibited <sup>12</sup> via CB<sub>2</sub>.


The ultimate outcomes of CB<sub>2</sub> activation in immune cells include inhibition of proliferation, induction of apoptosis, influences on cytokine/chemokine networks, and regulation of adhesion and migration <sup>reviewed in 26</sup>. In human immunocompetent cells CB<sub>2</sub> activation inhibits IL-2 <sup>e.g. 27</sup>, IL-17, INF- $\gamma$ , TNF- $\alpha$  <sup>e.g. 28</sup> secretion, and stimulates IL-4 <sup>29</sup> and TGF- $\beta$  <sup>30</sup> secretion. Murine *in vitro* and *in vivo* models indicate that cannabinoids inhibit IL-2 <sup>31</sup>, IL-12 and IFN- $\gamma$  <sup>32,33</sup>, and induce IL-4 secretion <sup>32,33</sup>. However, these studies stimulated leukocytes with mitogens or antibodies. Species differences in cannabinoid signaling notwithstanding <sup>e.g. 5</sup>, cytokine secretion is generally highly dependent on cellular environment. Indeed, cannabinoid effects on the cytokine network are sensitive to the method of cell activation <sup>34</sup>.

Therefore, close to the entirety of our current understanding of CB<sub>2</sub> signaling and influence on the cytokine secretome has been obtained from models which exhibit considerable limitations in modelling normal human physiology. We endeavored to carry out a comprehensive study of CB<sub>2</sub> signaling in unstimulated human primary leukocytes (peripheral blood mononuclear cells, PBMC) under conditions closely preserving their *in vivo* state. We have observed an unprecedented CB<sub>2</sub>-mediated signaling and functional profile, including coupling to G $\alpha_s$ .

## Results

### CB<sub>2</sub>, but not CB<sub>1</sub>, is expressed in unstimulated human primary PBMC

We quantified expression of CB<sub>1</sub> and CB<sub>2</sub> protein by whole cell radioligand binding with high affinity CB<sub>1</sub>/CB<sub>2</sub> ligand [<sup>3</sup>H]-CP55940 displaced by CB<sub>1</sub>- and CB<sub>2</sub>- selective ligands, ACEA<sup>35</sup> and HU308<sup>36</sup> respectively. Although CB<sub>2</sub> was expected to be the primary cannabinoid-responsive receptor in human PBMC, CB<sub>1</sub> transcripts have also been detected in some contexts e.g. 1. Whereas CB<sub>1</sub> protein could not be detected in PBMC from any of three healthy human donors, CB<sub>2</sub> was readily detectable (Fig. 1). Intra-subject variability in CB<sub>2</sub> expression was low (independent experiments are from three blood draws from the same donor taken over the course of up to 8 months), while inter-subject expression was within the same magnitude, ranging from 704 to 1323 fmol/mg. PBMC samples from these same three donors were utilized in subsequent experiments.



**Fig. 1. CB<sub>1</sub> and CB<sub>2</sub> protein quantification by whole cell radioligand binding.** Cells were incubated with [<sup>3</sup>H]-CP55940 (5nM) in the presence and absence of a CB<sub>1</sub>-selective displacer ACEA (1μM), or a CB<sub>2</sub>-selective displacer HU308 (1μM). Total binding sites (B<sub>max</sub>) were calculated (see methods) and converted to fmol/mg of total protein. HEK wt is a negative control

(not expressing CB<sub>1</sub> or CB<sub>2</sub>), HEK-hCB<sub>1</sub> is a positive control for CB<sub>1</sub>, HEK-hCB<sub>2</sub> is a positive control for CB<sub>2</sub>. PBMC A, B, and C are from subjects A, B, and C, respectively. The graph shows independent experiment means (from technical triplicate) as well as overall mean  $\pm$  SEM of these three independent experiments each performed with cells from a separate subject (three subjects in total).

### **CB<sub>2</sub> activation induces simultaneous G<sub>α<sub>i</sub></sub> and G<sub>α<sub>s</sub></sub> coupling, producing delayed cAMP flux**

CB<sub>2</sub> is widely recognized to inhibit cAMP production via G<sub>α<sub>i/o</sub></sub> inhibition of adenylyl cyclases. Depending on basal adenylyl cyclase activity in the sample of interest, stimulation of adenylyl cyclase (e.g. with forskolin) is a typical prerequisite for measuring inhibition<sup>4,10</sup>. We first studied the time-course of cAMP signaling in PBMC in response to CB<sub>2</sub>-selective agonist HU308 (1 μM), and observed inhibition of forskolin-stimulated cAMP synthesis in line with our general expectations (Fig. 2A). However, there was a lag to the onset of measurable inhibition which lasted at least 10 min, with the 20-35 min time-points being significantly different from time-matched vehicle control ( $p < 0.01$ ). This was followed by a steady reduction in cAMP concentration, reaching a maximum extent by 30 min (to  $60.3 \pm 2.8\%$  of forskolin-stimulated), with cAMP subsequently returning back to the forskolin-induced level by 60 min. Prior studies in cells overexpressing CB<sub>2</sub> describe an immediate onset and earlier peak cAMP inhibition<sup>37</sup>. Given that we cannot readily measure inhibition of cAMP production without forskolin being present, we hypothesized that low basal cAMP and/or slow response to forskolin in the primary leukocytes might mask the ability to detect inhibition at early time-points and hence produce the observed delay. However, pre-incubation with forskolin prior to HU308 addition did not

influence the signaling latency, time to peak response, nor efficacy, therefore ruling out this hypothesis (Fig. S1).


Pre-incubation with pertussis toxin (PTX), a  $G\alpha_i$  e.g. <sup>38</sup> and  $G\alpha_i$ -derived  $\beta\gamma$  reviewed in <sup>39</sup> inhibitor, followed by its co-application with HU308 revealed a wave of increased cAMP (Fig. 2A). This induction of cAMP accumulation had an earlier onset than the net cAMP inhibition (without PTX), with peak activation at around 10 min, and a slower return to forskolin-stimulated levels than the net cAMP flux, with the 7-25 min time-points being significantly different from time-matched vehicle control ( $p < 0.01$ ). Given that increased cAMP is associated with  $G\alpha_s$  coupling, we tested the effect of  $G\alpha_s$ -blocker NF449 e.g. <sup>40</sup> on HU308-stimulated cAMP flux. In comparison with net cAMP flux, not only was the peak of inhibition shifted to an earlier time-point (20 min), but the onset of cAMP inhibition had no apparent delay, with the 3-35 min time-points being significantly different from time-matched vehicle control ( $p < 0.01$ ). The time-courses for onset of reduction and return to forskolin-stimulated cAMP levels for this now apparently “pure” inhibitory signaling had similar timing.

These findings indicate that when no signaling inhibitors are present the opposing influences of  $G\alpha_i$  and  $G\alpha_s$  coupling produce a net apparent “lag” to the onset cAMP flux. At later time-points, the different time-courses and relative efficacies of  $G\alpha_i$  versus  $G\alpha_s$  coupling to adenylyl cyclase(s) result in transient net inhibition of cAMP synthesis. Increased cAMP in response to HU308 was detectable even without forskolin stimulation, although inhibition of  $G\alpha_i$  was required to reveal this as was the case when forskolin was present (Fig. S2).

cAMP fluxes for the three types of responses at their respective peak time-points (net cAMP, 30 min; cAMP accumulation, 10 min; cAMP inhibition, 20 min) were of nanomolar potency, typical for CB<sub>2</sub>-mediated signaling by HU308 <sup>5,41</sup>, with subtle differences in potencies between the three cAMP responses with rank order: stimulatory cAMP > “pure” inhibitory > net cAMP

(Fig. 2B, S3). Not surprisingly from the opposing effects on cAMP concentration, the peak stimulatory and “pure” inhibitory cAMP responses revealed by the  $G\alpha$  inhibitors had greater efficacies than the maximal net cAMP response (Fig. 2C, S3). Between-subject variability was small.

We further probed the contribution of G proteins (Fig. 2D) and investigated CB<sub>2</sub>-specificity (Fig. 2E). As expected from the time-course data,  $G\alpha_s$  inhibitor NF449 had a minimal effect on the net cAMP response peak (30 min), while  $G\alpha_{i/o}/\beta\gamma$  inhibitor PTX and  $G\alpha_i$  inhibitor NF023<sup>e.g. 42</sup> blocked the HU308-induced inhibition of cAMP synthesis. The “pure” inhibitory response (in the presence of NF449) was also completely blocked by the  $G\alpha_{i/o}$  inhibitors. In contrast, the peak stimulation of cAMP synthesis (measured in the presence of PTX) was completely blocked by  $G\alpha_s$  inhibitor NF449. A  $G\beta\gamma$  inhibitor gallein<sup>e.g. 43</sup> had no effect on cAMP signaling, indicating lack of  $G\beta\gamma$  involvement (Fig. 2D). As well as the potencies of HU308-induced cAMP flux being consistent with CB<sub>2</sub>-specific responses, inverse agonist SR144528<sup>44</sup> at 1  $\mu$ M (a concentration at which it binds to CB<sub>2</sub>, but not to CB<sub>1</sub>, Fig. S4) completely blocked cAMP signaling induced by HU308 (Fig. 2E). Inverse agonism of SR144528 was readily measurable for the inhibitory and net cAMP pathways ( $p < 0.001$ ), in which it increased cAMP above forskolin-induced levels. There was a trend toward inverse agonism in the stimulatory cAMP pathway, but this reduction in cAMP was not significantly different from forskolin alone ( $p = 0.78$ ). A CB<sub>1</sub>/CB<sub>2</sub> neutral antagonist WIN55212-3<sup>45,46</sup> (no significant differences from forskolin control,  $p < 0.05$ ) also completely abrogated all HU308-induced cAMP signaling (Fig. 2E). Given the lack of CB<sub>1</sub> protein in PBMC (Fig. 1), WIN55212-3 most likely acted via CB<sub>2</sub>, and taken together with the SR144528 data and response potencies provides strong evidence that the observed signaling is CB<sub>2</sub>-mediated.




**Fig. 2. cAMP signaling in human primary PBMC.** **A.** PBMC were incubated with 10µM forskolin (FSK) and HU308 (1µM) without inhibitors (●), or after pre-treatment with NF449 (10µM for 30 min, ■), or with PTX (100ng/mL for 6 h, ▲). The graph shows mean ± SEM of three independent experiments performed in technical triplicate, each with cells from a separate subject (three subjects in total). **B, C.** HU308 concentration-response curve parameters; potency (**B**) and efficacy (**C**; span of curves as in Fig. S3). **D, E.** Stimulations were with 10µM forskolin and 1µM HU308 or vehicle for 30 min for net cAMP flux, 10 min for the stimulatory pathway (revealed by PTX), or 20 min for the inhibitory pathway (revealed by NF449). **D.** PBMC were additionally pre-treated as indicated with PTX, NF449, NF023 or gallein. Data are normalized to vehicle control as 0% and forskolin controls with matching inhibitors as 100%. Statistical comparisons are to the vehicle plus HU308 control within each set. **E.** PBMC were

pre-treated as indicated, then co-incubated with forskolin (10 $\mu$ M), SR144528 (SR2, 1 $\mu$ M) or WIN55212-3 (WIN-3, 5 $\mu$ M), and HU308 (100nM) or vehicle for 10, 20, or 30 min. Data are normalized to vehicle control as 0% and forskolin control as 100%. All SR2 and WIN-3 conditions were significantly different from “HU308” control for peak signaling within each set ( $P < 0.001$ ). Within each set, condition “SR2” was compared to “SR2 + HU308”, “WIN3” was compared to “WIN3 + HU308”, and had no significant difference. Graphs **B-E** show independent experiment means (from technical triplicate) as well as overall mean  $\pm$  SEM of these three independent experiments each performed with cells from a separate subject (three subjects in total).

### **CB<sub>2</sub>-stimulated phosphorylation of ERK1/2 is mediated by G $\alpha_i$ - but not G $\alpha_s$ -coupled G $\beta\gamma$**

Phosphorylation of ERK1/2 (p-ERK) is a widely observed CB<sub>2</sub> response, but the potential pathways to stimulation are many and varied and p-ERK can act as an integrator of responses reviewed in 47. Time-courses with 1 $\mu$ M HU308 revealed transient activation of p-ERK, with a peak at around 3 min (Fig. 3A). HU308 activated ERK1/2 in a concentration-dependent manner (Fig. S5), with approximately one log unit lower potency than observed for cAMP fluxes (pEC<sub>50</sub> 7.69  $\pm$  0.06). Responses were very consistent between the three donors. Neither G $\alpha_i$  inhibitor NF023 nor G $\alpha_s$  inhibitor NF449 had an effect on the observed ERK1/2 signaling (Fig. 3B), whereas G $\alpha_i/o/\beta\gamma$  inhibitor PTX and G $\beta\gamma$  inhibitor gallein both completely blocked activation of p-ERK. This indicates that p-ERK1/2 induced by HU308 is mediated by G $\alpha_i$ -linked  $\beta\gamma$  dimers. We further verified that the observed p-ERK1/2 response was CB<sub>2</sub>-mediated by co-applying HU308 with SR144528 or WIN55212-3 (Fig. 3C). Both antagonists completely blocked p-ERK, supporting the inference that HU308 binding to CB<sub>2</sub> receptors is the only initiator of the measured p-ERK


signal. Furthermore, we observed no p-ERK response for CB<sub>1</sub>-selective agonist ACEA at 1 $\mu$ M (Fig. S6), a concentration which binds to CB<sub>1</sub> but not CB<sub>2</sub> (Fig. 1) and can induce CB<sub>1</sub>-mediated p-ERK e.g. 48.



**Fig. 3. ERK1/2 signaling in human primary PBMC. A.** Time-course with 1 $\mu$ M HU308 (■) or a vehicle control (●). 2, 3, and 4 min time-points are significantly different from time matched vehicle controls ( $p < 0.01$ ). The graph shows mean  $\pm$  SEM of three independent experiments performed in technical triplicate, each with cells from a separate subject (three subjects in total). **B.** 3 min incubation with HU308 (1 $\mu$ M) or vehicle control in the presence of G protein inhibitors PTX, gallein, NF023, NF449 or vehicle control. **C.** 3 min incubation with HU308 (100nM) or vehicle control in the presence of SR144528 (SR2, 1 $\mu$ M), WIN55212-3 (WIN-3, 5 $\mu$ M), or vehicle control. Data are normalized to vehicle control (100%). Graphs **B,C** show independent experiment means (from technical triplicate) as well as overall mean  $\pm$  SEM of these three independent experiments each performed with cells from a separate subject (three subjects in total).

# **CB<sub>2</sub> induces phosphorylation of p38 via G $\alpha_i$ and Akt via G $\beta\gamma$ , but does not activate JNK**

Time-courses stimulating PBMC with 1 $\mu$ M HU308 revealed phosphorylation of Akt and p38 with signaling peaks at around 20 min, and with similar overall kinetics (Fig. 4A). Conversely, there was no phosphorylation of JNK detected. Application of PTX completely abrogated Akt and p38 phosphorylation (Fig. 4B), implicating the involvement of G $\alpha_i/\beta\gamma$  proteins. G $\beta\gamma$  inhibitor gallein completely blocked p-Akt, but did not influence p-p38 (Fig. 4B). HU308 therefore induces phosphorylation of p38 downstream of G $\alpha_i$  subunits, while Akt is activated via G $\alpha_i$ -coupled  $\beta\gamma$  heterodimers.




**Fig. 4. Phosphorylation of Akt, JNK, and p38 MAP kinases in human primary PBMC. A.**

Time-courses with HU308 (1 $\mu$ M) and vehicle control. For p-Akt and p-p38 time-points 10-30 min are significantly different from time-matched vehicle controls ( $p < 0.05$ ). For p-JNK, all points are indistinguishable from 0 min. The graph shows mean  $\pm$  SEM of three independent experiments performed in technical triplicate, each with cells from a separate subject (three subjects in total). **B.** Responses to 20 min 1 $\mu$ M HU308 after pre-treatment with PTX, gallein or vehicle control at. Data are normalized and statistically compared to the corresponding vehicle plus HU308 control. The graph shows independent experiment means (from technical triplicate)

as well as overall mean  $\pm$  SEM of these three independent experiments each performed with cells from a separate subject (three subjects in total).

## **CB<sub>2</sub> induces p-CREB downstream of G $\alpha_s$ and G $\beta\gamma$**

CREB phosphorylation is a classical downstream consequence of G $\alpha_s$  and cAMP-mediated activation of protein kinase A (PKA) <sup>reviewed in 49</sup>. A time-course with PBMC stimulated by 1 $\mu$ M HU308 (Fig. 5A) revealed a wave of CREB phosphorylation which was maximal around 30-40 min and resolved by 60 min. We applied G protein inhibitors NF023, NF449, gallein and PTX (Fig. 5B), and found that both NF449 and gallein each partially inhibit CREB phosphorylation to a similar degree, but almost completely block the HU308 response when co-applied indicating that G $\alpha_s$  and  $\beta\gamma$  heterodimers are similarly important in CREB phosphorylation in this context. p-CREB was reduced by PTX and NF023 to a lesser extent, with equivalent efficacy to each other, implying a minor involvement of G $\alpha_i$  but not G $\alpha_i$ -coupled  $\beta\gamma$  in p-CREB activation. SR144528 and WIN55212-3 completely blocked the peak CREB phosphorylation (Fig. 5C), indicating that this pathway activation occurs downstream of CB<sub>2</sub>. SR144528 reduced p-CREB relative to the vehicle control indicating that this compound acted as an inverse agonist ( $p < 0.05$ ).




**Fig. 5. Phosphorylation of CREB in human primary PBMC. A.** Time-course with HU308 (1μM) and vehicle control. 10-50 min time-points are significantly different from time-matched vehicle controls ( $p < 0.01$ ). The graph shows mean  $\pm$  SEM of three independent experiments performed in technical triplicate, each with cells from a separate subject (three subjects in total). **B.** p-CREB stimulated by HU308 (1μM) for 40 min in the presence of G protein inhibitors gallein, NF023, NF449, PTX or vehicle control; data are normalized to responses in the absence of HU308 (100%); statistical comparisons are to the HU308 response without inhibitors. **C.** p-CREB stimulated by a CB<sub>2</sub>-selective agonist HU308 (100nM) or vehicle control at 40 min in the presence of a CB<sub>2</sub>-selective inverse agonist/antagonist SR144528 (SR2, 1μM), a CB<sub>1</sub>/CB<sub>2</sub> neutral antagonist WIN55212-3 (WIN-3, 5μM), or vehicle control; data are normalized to vehicle control (100%). Graphs **B,C** show independent experiment means (from technical triplicate) as well as overall mean  $\pm$  SEM of these three independent experiments each performed with cells from a separate subject (three subjects in total).

## **CB<sub>2</sub> activation induces secretion of cytokines IL-6 and IL-10**

We stimulated PBMC with HU308 under the same conditions as used for the signaling assays and detected cytokines released into the assay media. After 12 hours, interleukin 6 (IL-6) and 10 (IL-10) concentrations were significantly different from vehicle-treated cells ( $p < 0.01$ ), whereas the remaining 7 cytokines in our panel (IL-2, IL-4, IL-12, IL-13, IL-17A, MIP-1 $\alpha$ , and TNF- $\alpha$ ) were indistinguishable from vehicle-treated cells (Fig. S7). HU308 was also co-applied with forskolin (10 $\mu$ M) to mimic conditions of our cAMP signaling assays; this had no effect by itself and did not influence the HU308-mediated IL-6 and IL-10 levels (Fig. S7). The responses were very similar between PBMC from 3 subjects and cell numbers were unaffected by the applied ligands (Fig. S8). Subsequent interleukin experiments were carried out *without* forskolin present.


IL-6 and IL-10 accumulation were also detectable at an earlier time-point – after 6 h of HU308 stimulation (Fig. 6A). This was concentration-dependent, with HU308 having greater potency for inducing IL-10 (pEC<sub>50</sub> 10.06  $\pm$  0.08 and 9.55  $\pm$  0.04;  $p = 0.005$ , unpaired t test). Application of G protein inhibitors revealed that HU308-induced IL-6 and IL-10 secretion are almost fully blocked by G $\alpha_s$  inhibitor NF449, partially blocked by  $\beta\gamma$  inhibitor gallein, and to a lesser extent sensitive to G $\alpha_i$  inhibitor NF023 (Fig. 6B, 6C). Responses to HU308 (10nM) were fully abrogated by SR144528 (1 $\mu$ M) and WIN55212-3 (5 $\mu$ M) down to levels below the assays' limits of quantitation. SR144528 and WIN55212-3 had no measurable effects on IL-6 or IL-10 production when applied alone.



**Fig. 6. Induction of cytokine secretion by PBMC.** **A.** Induction of IL-6 and IL-10 secretion in response to 6 h incubation with HU308. Lipopolysaccharide (LPS, 10ng/mL) is a positive control. The graph shows mean  $\pm$  SEM of three independent experiments performed in technical triplicate, each with cells from a separate subject (three subjects in total). **B.** IL-6 and **C.** IL-10 accumulation in the presence of G protein inhibitors or CB2 antagonists: PBMC were pre-treated with gallein, NF023, NF449, SR144528 (SR2, 1 $\mu$ M), or WIN55212-3 (WIN-3, 5 $\mu$ M) for 30 min followed by 6-hour treatments with HU308 (10nM) with the inhibitors/antagonists present for the entire duration of incubation; data are normalized to HU308 responses without inhibitors/antagonists. Effects of inhibitors on HU308 responses were statistically compared with the corresponding HU308 response without inhibitor. In the presence of SR2 and WIN-3, there was no statistical difference between HU308 and the HU308 vehicle control. Graphs **B,C** show independent experiment means (from technical triplicate) as well as overall mean  $\pm$  SEM of these three independent experiments each performed with cells from a separate subject (three subjects in total).

# Discussion

To our knowledge this study represents the first investigation of CB<sub>2</sub> signaling and functional implications thereof in unstimulated human primary PBMC. Cells were kept in culture for as little time as practically possible (up to 6 hours prior to stimuli of interest) and in 10% serum in order to mimic the state of leukocytes *in vivo*; a unique experimental paradigm in comparison with the vast majority of other cannabinoid studies to date. Obtaining an accurate understanding of CB<sub>2</sub> function in normal cells is critical to meaningful interpretation of CB<sub>2</sub> function in abnormal conditions and in assessing therapeutic potential. The signaling profile we observed is summarized in Fig. 7.



**Fig. 7. CB<sub>2</sub> signaling network in mixed human primary leukocytes.** Binding of HU308 to CB<sub>2</sub> leads to activation of Gα<sub>i</sub>βγ and Gα<sub>s</sub>βγ heterotrimers. Gα<sub>i</sub> inhibits adenylyl cyclase(s) (AC) and activates a cascade leading to phosphorylation of p38 and CREB. βγ from Gα<sub>i</sub>βγ activates

Akt and initiates a cascade leading to phosphorylation of ERK.  $G_{\alpha_s}$  stimulates AC which leads (likely via protein kinase A, PKA) to p-CREB.  $\beta\gamma$  from non- $G_{\alpha_i}\beta\gamma$  (likely from  $G_{\alpha_s}\beta\gamma$ ) also contributes to p-CREB activation. Based on inhibitor effects (Fig. 5B),  $G_{\alpha_s}$  and non- $G_{\alpha_i}\beta\gamma$  are the major mediators of p-CREB, whereas p-p38 is a minor p-CREB mediator. JNK phosphorylation was not observed. Given that  $G_{\alpha_i}$ -mediated inhibition of AC does not inhibit p-CREB activation it is likely that  $G_{\alpha_i}$  and  $G_{\alpha_s}$  modulation of AC are either segregated in separate compartments within one cell, or occur in different cells (represented by vertical dotted line). p-CREB likely mediates IL-6/IL-10 induction, which might be released from one cell or from different cell types.

We found that human primary PBMC respond in a concentration-dependent manner to CB<sub>2</sub>-selective agonist HU308 with net inhibition of forskolin-induced cAMP synthesis, however a surprising feature was a latency of approximately 10 min prior to any measurable change in cAMP concentration. Application of  $G_{\alpha}$  inhibitors revealed that CB<sub>2</sub> simultaneously activates stimulatory and inhibitory cAMP pathways, explaining the apparent delay in net cAMP inhibition which arises from these oppositely-directed responses balancing each other at early time-points. Response potencies were consistent with CB<sub>2</sub> specificity and signaling was also sensitive to SR144528 and WIN55212-3, indicating that the observed signaling is CB<sub>2</sub>-mediated. Although the idea that CB<sub>2</sub> may couple promiscuously to G proteins is not unprecedented<sup>6,10</sup>, to our knowledge CB<sub>2</sub> coupling to  $G_{\alpha_s}$  has not been reported previously.

Börner and colleagues<sup>8</sup> observed stimulatory effects of CB<sub>1</sub>/CB<sub>2</sub> mixed agonists JWH015, THC and methanandamide on cAMP concentrations in IL-4-stimulated human primary T lymphocytes after prolonged cannabinoid incubations, however cAMP increases were sensitive

to PTX and therefore concluded to be downstream of  $G\alpha_i$ , likely via  $\beta\gamma$  <sup>8</sup>. Promiscuous coupling of other receptors to  $G\alpha_i$  and  $G\alpha_s$  has been observed, including  $CB_1$  in our own hands <sup>50</sup>. However, we did not observe  $G\alpha_s$  coupling of human  $CB_2$  in this same model. Studies in other models have also applied PTX and not revealed  $CB_2$  signaling consistent with  $G\alpha_s$  coupling <sup>e.g. 10,51,52</sup>. We therefore speculate that a critical component of the  $CB_2$  immune cell signaling landscape has not been captured in previously studied models.

As we have studied mixed PBMC we cannot provide direct evidence as to whether both cAMP inhibition and stimulation have been induced in the same cell or if our findings arise as a result of assaying a mixture of  $G\alpha_i$ -predominant versus  $G\alpha_s$ -predominant cell types. Leukocytes are known to express  $G\alpha_i$  <sup>e.g. 53,54</sup>,  $G\alpha_s$  <sup>reviewed in 39</sup>, and  $G\alpha_i/s$ -sensitive adenylyl cyclases <sup>e.g. 55</sup>. However, balance between  $G\alpha$  and  $G\beta\gamma$  subunit expression may determine overall cAMP responses <sup>56</sup>. As well, adenylyl cyclase isoforms can differ in their  $G\alpha$  sensitivities and expression levels can vary between immune cell types <sup>55</sup>. Furthermore, G protein coupling “switches” have been reported for receptors in heterodimers <sup>57,58</sup>. The particular profile and stoichiometries of interaction partners can give rise to differential signaling “units” between cell types <sup>reviewed in 59</sup>. There are also various explanations for potential dual coupling within the same cell. Signalsome subcellular compartmentalization and/or sequestration of signaling components is one example <sup>reviewed in 60</sup>; indeed subcellular distribution of  $CB_2$  can influence  $CB_2$  signaling patterns <sup>6</sup>, and  $CB_2$  seems to have a particularly unique distribution in immune cells <sup>61–63</sup>. Homologous signaling feedback upon  $CB_2$  activation which results in rapid desensitization of  $G\alpha_s$  coupling with little or slower influence on  $G\alpha_i$  coupling such as via differential phosphorylation by G Protein-Coupled Receptor Kinases or PKA <sup>64–66</sup> might assist in explaining the observed cAMP signaling profile.  $G\beta\gamma$  exhaustion/sequestration may also hinder  $G\alpha_s$  activation <sup>67,68</sup>. It is also important to note, and intriguing regarding the downstream functional

implications, that subcellular compartmentalization of G proteins and/or adenylyl cyclase subtypes could give rise to localized cAMP fluxes, implying that simultaneous effects of both cAMP increases and decreases are possible even when the net cAMP concentration is unchanged<sup>reviewed in 69</sup>.

The ERK1/2 signaling cascade regulates cell cycle progression<sup>reviewed in 70</sup>, immunological functions, including differentiation of T lymphocytes<sup>13</sup>, polarization of CD4<sup>+</sup> T lymphocytes<sup>71</sup>, and regulation of cytokine network<sup>e.g. 72</sup>, and is dysregulated in a number of disease states<sup>e.g. 23</sup>. We find that human primary PBMC respond to CB<sub>2</sub> activation by HU308 with rapid and transient stimulation of p-ERK. As this was completely sensitive to both Gβγ inhibitor gallein and Gα<sub>i/o</sub>/βγ inhibitor PTX, we conclude that ERK1/2 phosphorylation induced by HU308 is mediated by βγ dimers of Gαβγ heterotrimeric proteins. Although in some systems gallein may inhibit GRK2 and possibly associated arrestin signaling<sup>73</sup>, we do not know of any studies suggesting that PTX blocks arrestin-initiated signaling other than one report of a small potency shift for arrestin recruitment<sup>74</sup>. Interestingly NF023, which we confirmed in cAMP assays inhibits Gα<sub>i</sub>, did not block the p-ERK response, indicating that this blocker specifically inhibits Gα subunits without influencing Gβγ activity as also observed previously<sup>75</sup>. HU308 also induced phosphorylation of p38 and Akt. p-p38 was mediated by Gα<sub>i/o</sub> subunits of G proteins (possibly via Src kinase)<sup>e.g. 76</sup>, as it was completely blocked by Gα<sub>i/o</sub>/βγ inhibitor PTX but not by Gβγ inhibitor gallein, whereas p-Akt was mediated by Gα<sub>i/o</sub>-coupled βγ heterodimers (fully blocked by PTX and gallein).

In contrast with prior studies in human promyelocytic leukemia HL60 cells<sup>25</sup> and CB<sub>2</sub>-overexpressing HEK cells<sup>24</sup> we did not observe JNK phosphorylation. However, we note that activation of this pathway may be cell-context dependent given that in LPS-stimulated human monocytes JNK was inhibited by a CB<sub>2</sub> ligand<sup>12</sup>. Another explanation may be a different CB<sub>2</sub>-

mediated functional profile (i.e. biased agonism) between HU308 and the previously studied ligands <sup>5,77</sup>. There may also be signal-modifying influences of serum as has been shown for CB<sub>1</sub> <sup>78</sup>. The serum factors that circulating immune cells would be exposed to *in situ* are likely to influence signaling patterns <sup>79</sup>. We therefore feel that inclusion of 10% fetal bovine serum is an important methodological improvement upon earlier studies carried out under low serum or serum-free conditions. However, we must acknowledge that this is of course not a perfect model of human serum from the matched donor. Some of the resistance to inclusion of serum in cannabinoid signaling studies is the potential for presence of endocannabinoids and precursor molecules which would complicate the interpretation of reductionist experiments e.g. <sup>80</sup>. However, careful attention to vehicle controls, the potency of HU308 effects, only subtle inverse agonist effects, and lack of effects of a neutral antagonist when applied alone, indicate that any influence in this regard was minimal to non-existent in our study.

cAMP/PKA, MAP kinases ERK and p38, and Akt/PKB all have the potential to induce phosphorylation of CREB reviewed in <sup>49</sup>. Immunological functions of p-CREB include anti-apoptotic effects on macrophages via p-38 <sup>81</sup>, proliferative effects on T lymphocytes via p-38 <sup>82</sup> and p-ERK <sup>83</sup>, and activation/proliferation of B lymphocytes via p-ERK <sup>84</sup>. CB<sub>2</sub>-mediated p-CREB activation in primary PBMC is mediated primarily and to a similar degree by G $\alpha_s$  subunits and non-G $\alpha_i$ -derived  $\beta\gamma$  dimers, and to a limited extent by G $\alpha_i$  subunits. Though G $\alpha_s$ -coupled  $\beta\gamma$  is not widely appreciated to induce signaling events, at least a few examples exist in the literature e.g. <sup>85,86</sup>. p-CREB is unlikely to be downstream of pERK or p-Akt in our system given that these pathways were both associated with  $\beta\gamma$  from G $\alpha_i\beta\gamma$  heterotrimers, however G $\alpha_i$ -coupled p-p38 may be involved to a minor degree. One of the primary p-CREB activation pathways is likely via G $\alpha_s$  leading to cAMP-activated PKA. This is interesting given that when measuring cAMP concentrations we did not detect any increase unless a G $\alpha_i$  blocker was present. This implies

that the consequences of  $G_{\alpha i}$  versus  $G_{\alpha s}$  activation on cAMP concentration are distinct, supporting theories that either CB<sub>2</sub> is signaling differently between cell types or that subcellular compartmentalization can give rise to differential local cAMP concentrations with independent consequences for signaling.

Proceeding to study a physiologically relevant outcome, we detected a CB<sub>2</sub>-mediated induction of interleukins 6 and 10 at 6 and 12 h. Both were sensitive to NF449 > gallein > NF023, indicating that  $G_{\alpha s}$  is the main contributor to these responses. This pattern of influence of G protein inhibitors was similar to that for p-CREB, and given that p-CREB can induce transcription of IL-6 and IL-10 genes <sup>reviewed in 87</sup>, it is very feasible that CREB phosphorylation is an important mediator of HU308-induced IL-6 and IL-10. Although in some instances IL-6 may be secreted from a pre-formed pool <sup>e.g. 88</sup> the observed induction of IL-6 by HU308 at 6 and 12 h likely involves its *de novo* synthesis <sup>e.g. 89</sup>. To our knowledge, PBMC do not have intracellular granules of IL-10, and so it is most likely being synthesized *de novo* and then secreted. Kinetics of mRNA induction for IL-6 and IL-10 <sup>e.g. 90,91</sup> are consistent with a multi-hour lag in their production after CB<sub>2</sub> activation.

Given that p-p38 was blocked by PTX and not gallein, this is a candidate for the NF023-sensitive ( $G_{\alpha i}$ -requiring) component of IL-6/10 induction. p-p38 and p-Akt have also been linked to both IL-6 <sup>e.g. 92,93</sup> and IL-10 production <sup>e.g. 94,95</sup>. Given the indicated involvement of CREB we were surprised to find that forskolin, a strong activator of signaling pathways downstream of adenylyl cyclases, did not influence cytokine secretion. We postulate that a co-stimulus enabled by CB<sub>2</sub> activation but not by forskolin might be required for IL-6/10 induction <sup>reviewed in 49</sup>. It is also plausible that the potential for subcellular compartmentalization and/or temporal integration of cAMP fluxes play critical roles. Application of specific signaling pathway inhibitors would be useful to more directly delineate the exact signaling pathways responsible.

The degree of cytokine induction we observed was small in comparison with the positive control utilized, LPS – a potent mediator of bacterial sepsis <sup>reviewed in 96</sup>, which models systemic inflammation *in vitro*. Given that HU308 was ~10 times less efficacious than LPS, it is unlikely that CB<sub>2</sub> activation would result in dramatic systemic inflammatory reactions *in vivo*, but might rather elicit immunomodulatory effects with a potential for both pro- and anti-inflammatory functions – likely depending on the state of the immune system.

We did not observe modulation of cytokines IL-2, IL-4, IL-12, IL-13, IL-17A, MIP-1α, or TNF-α, likely because we avoided activation of PBMC with mitogenic/antigenic proliferative or cytokine-inductive stimuli to preserve their *in vivo* phenotype and hence could not detect any potential inhibitory effects of HU308.

We also noted that HU308 did not influence cell number of PBMC treated for 6 and 12 h, which is *prima facie* unexpected given prior reports of cannabinoid-induced cell death. However, these prior studies were carried out under completely different experimental paradigms <sup>17, e.g. 97,98</sup>. Furthermore, this response has been found to be cell type- and ligand-dependent <sup>reviewed in 99</sup>, and is not always mediated by cannabinoid receptors <sup>e.g. 100</sup>.

IL-10 is an anti-inflammatory cytokine expressed by many immunocompetent cell types which regulates T-lymphocytic responses via direct mechanisms <sup>e.g. 101</sup> and by inhibiting effector functions of antigen-presenting cells <sup>e.g. 102,103</sup>. IL-10 can also protect from excessive immunoreactivity by inhibiting overproduction of cytokines, *including* IL-6 which is widely described as pro-inflammatory. Typical IL-6 effects include induction of acute phase proteins, monocyte recruitment and macrophage infiltration, activation of plasma cells, and CD4+ lymphocyte differentiation <sup>reviewed in 104</sup>. Based on these paradigms the combined release of IL-6 and IL-10 seems counter-intuitive. However, IL-6 can context-dependently exert anti-

inflammatory effects, and indeed simultaneous production of IL-6 and IL-10 from mixed human primary immune cells has been observed previously <sup>105</sup>.

The HU308-induced production of both IL-6 and IL-10 within the same time-frame, and with strikingly similar potencies and patterns of influence by inhibitors, seem to imply that CB<sub>2</sub> either stimulates release of one cytokine which induces the second, or that the two cytokines are induced via the same signaling pathways. Considerable literature supports the first possibility; for example, IL-6 in concert with other cytokines can stimulate differentiation of naïve CD4<sup>+</sup> T cells into IL-10-producing regulatory type 1 helper T (Tr1) or IL-17-producing T helper (T<sub>H</sub>-17) cells which have anti-inflammatory effects *in vivo* <sup>106,107</sup>. Low dose recombinant IL-6 can also increase plasma IL-10 and have other anti-inflammatory effects in humans <sup>108</sup>. However, given the acute time-frame within which we detected both IL-6 and IL-10 (by 6h), and slightly greater potency of the IL-10 response, it seems unlikely that in our system CB<sub>2</sub> activation first induces IL-6 which subsequently leads to IL-10 secretion from a different cell type. It is possible that IL-6 and IL-10 were released independently from different cells, however, the near-identical profile of sensitivity to G protein inhibitors leads us to suspect that the most plausible scenario is that IL-6 and IL-10 are generated from the same cell type(s) in our system. Interestingly, these cytokines have coordinated mRNA regulation via the same nuclear site <sup>109</sup>. IL-6 and IL-10 have classically been thought to be produced by T helper 2 (Th2) T lymphocytes <sup>110</sup>, reviewed in <sup>111</sup>, while concurrent production has been observed in monocytes, tumor-associated macrophages and dendritic cells <sup>112–114</sup>. In future work it will be important to clarify the influence of CB<sub>2</sub> activation on different immune subtypes and this knowledge will also assist in designing follow-on experiments to investigate other CB<sub>2</sub>-mediated immune cell functions.

There is some precedent for cannabinoid mediation of both IL-6 and IL-10. Endocannabinoids upregulated IL-6 in LPS-stimulated U937 cells <sup>80</sup> and in whole blood cultures <sup>115</sup>. Cannabinoid-

mediated IL-10 induction has been shown *in vivo* in mice <sup>116</sup>, in murine LPS-stimulated macrophages <sup>11</sup>, and in murine encephalitogenic T lymphocytes <sup>117</sup>; the latter study also shows inhibition of IL-6 by cannabinoids, likely indicating species and/or cell type specificity. To our knowledge, CB<sub>2</sub>-mediated IL-10 production by human PBMC has never been shown before.

Historically, there is a considerable body of data regarding the general effects of cannabis and THC on human immune function, though somewhat surprisingly, little has been reported on cytokine profiles <sup>reviewed in 118,119</sup>. Increased serum IL-10 has been correlated with cannabis consumption <sup>120</sup>, while elevated IL-6 and other pro-inflammatory markers were found in individuals with cannabis dependency <sup>121</sup>. In a trial of THC in multiple sclerosis, cannabinoid treatments were found not to influence serum concentrations of IL-10 or CRP (a surrogate measure of IL-6), nor other measured cytokines, though sample sizes were small and variability between subjects large <sup>122</sup>. Further, THC is a partial agonist at CB<sub>2</sub> and so may have only subtle effects in comparison with full agonists. Only a few clinical trials of CB<sub>2</sub>-selective agonists have been undertaken and to our knowledge none have reported on cytokine profiles. We have also noted serious adverse effects from illicit synthetic cannabinoids, some of which are potent CB<sub>2</sub> agonists <sup>123,124</sup>. Although these adverse symptoms may be mediated by a non-cannabinoid-receptor target <sup>e.g. 125</sup>, we wonder whether a potent and efficacious influence on cytokine balance and/or different cytokine profile arising from biased agonism via CB<sub>2</sub> could contribute to deleterious effects.

The results of this study greatly expand our knowledge of CB<sub>2</sub> signaling and functional implications in human primary PBMC under conditions closely preserving their *in situ* state. The discovery of unprecedented CB<sub>2</sub> coupling to stimulatory (G $\alpha_s$ ) proteins, their simultaneous activation alongside inhibitory (G $\alpha_i$ ) proteins in a cAMP pathway, of G $\alpha_s$ -mediated effects on CREB phosphorylation, and of IL-6 and IL-10 induction, offer new perspectives on CB<sub>2</sub> signaling

and function which may be useful for drug discovery and investigations of CB<sub>2</sub> signaling phenomena including functional selectivity. The effects of CB<sub>2</sub> agonism we have observed in this study raise a number of questions and potential challenges, but reinforce the potential utility of CB<sub>2</sub> ligands as immunomodulatory therapeutics.

## Methods

### *Preparation of Human PBMC*

Human primary PBMC were isolated from blood samples collected from 3 healthy volunteers (male and female, aged 22-26) after obtaining written informed consents in accordance with ethical approval from the University of Auckland Human Participants Ethics Committee (#014035).

Whole venous blood samples, 50mL per draw, 3-6 draws per donor (with each set of experiments performed on one draw from each donor) were collected into K<sub>2</sub>EDTA-coated BD Vacutainer® Blood Collection Tubes (Becton, Dickinson and Company), transferred to polypropylene tubes (Corning), and diluted 1.25 volumes of blood with 1 volume RPMI 1640 medium (HyClone) supplemented with 2mM L-Glutamine (Thermo Fisher Scientific).

PBMC were isolated by gradient centrifugation in Histopaque®-1077 (Sigma-Aldrich) in Greiner Leucosep® 50mL tubes (Greiner Bio-One) for 15 min at 800×g at room temperature. The collected PBMC were washed twice with RPMI by centrifugation for 10 min at 250×g, re-suspended in a culture medium – RPMI supplemented with 10% v/v fetal bovine serum (FBS; New Zealand-origin, Moregate Biotech) and 2mM L-Glutamine. Following isolation, PBMC were either used in assays immediately, or cryopreserved in 50% RPMI with 40% FBS and 10%

DMSO and stored at -80°C for up to 12 months until later use. Cryopreservation did not affect CB<sub>2</sub> expression (Fig. S9) or HU308 signaling responses of PBMC (Fig. S10).

### ***Cell Lines and Cell Culture***

Human embryonic kidney (HEK) cell lines stably transfected with human CB<sub>1</sub> (HEK-hCB<sub>1</sub><sup>126</sup>) or human CB<sub>2</sub> (HEK-hCB<sub>2</sub><sup>50</sup>), or an untransfected wild type HEK Flp-in cell line (HEK wt, Invitrogen, R75007) were cultured in high-glucose DMEM (HyClone) with 10% v/v FBS, in the presence of Zeocin (InvivoGen) at 250µg/mL, Hygromycin B (Thermo Fisher Scientific) at 50µg/mL, or Zeocin at 100µg/mL, respectively.

### ***Whole Cell Radioligand Binding***

Human primary PBMC or HEK cells were pelleted by centrifugation for 10 min at 250×g or 5 min at 125×g respectively, and re-suspended in binding medium (RPMI with 1mg/mL BSA, 2mM L-Glutamine, 25mM HEPES). PBMC (3×10<sup>5</sup> cells per assay point), HEK-hCB<sub>1</sub> or HEK-hCB<sub>2</sub> (0.4×10<sup>5</sup> diluted in 1.6×10<sup>5</sup> HEK wt to avoid ligand depletion), or HEK wt (2×10<sup>5</sup>) cells were dispensed in Deep Well 96-well Plates (Gene Era Biotech) with reaction mix already present to produce a final 200µL reaction volume. The reaction mix included 5nM (final concentration) [<sup>3</sup>H]-CP55940 (PerkinElmer), and an appropriate displacer to measure non-specific displacement of the radioligand or a vehicle (DMSO) control to measure total binding of the radioligand. The displacer was either ACEA at 1µM (arachidonyl-2-chloroethylamide, synthesized from arachidonic acid as described in<sup>127</sup>), or HU308 at 1µM (Tocris Bioscience).

Plates were incubated on the surface of a 15°C thermostatic bath for 3 h to reach steady-state, then placed on ice. Reactions were then rapidly filtered under vacuum through GF/C glass fiber filter-bottom 96-well microplates (Perkin Elmer, MA, USA) pre-treated with 0.1% polyethyleneimine (PEI, Sigma-Aldrich). After three washes with ice-cold wash buffer (50mM HEPES pH 7.4, 500mM NaCl, 1mg/mL BSA) filter plates were dried overnight, then sealed, and

50µL per well Irgasafe Plus scintillation fluid (Perkin Elmer) was dispensed. After 30 min, plates were counted in a Wallac MicroBeta® TriLux Liquid Scintillation Counter (Perkin Elmer). Each independent experiment was verified to have undergone <10% ligand depletion. CB<sub>1</sub> and CB<sub>2</sub> protein quantification was based on the maximum binding parameter B<sub>max</sub>, the concentration of binding sites for the radioligand <sup>128</sup>, using the following formula based on equation 7.5.21 from 129.

$$B_{max} = \frac{\text{Specific binding}}{\text{Fractional occupancy}} = \frac{\text{Specific binding}}{[\text{Radioligand}] / (K_d + [\text{Radioligand}])}$$

B<sub>max</sub> were then converted to moles using the radioligand specific activity (as stated by the manufacturer), and then converted to units of fmol/mg of total protein added to an assay point (as measured by Bio-Rad DC Protein Assay Kit). Equilibrium dissociation constants (K<sub>d</sub>) for [<sup>3</sup>H]-CP55940 were measured by carrying out homologous competition binding under the same experimental conditions. pK<sub>d</sub> values were: 7.94 ± 0.04 at CB<sub>1</sub>, 7.80 ± 0.05 at CB<sub>2</sub> (*mean ± SEM*, *n*=3).

### **cAMP Assay**

PBMC were re-suspended in assay medium (RPMI with 2mM L-Glutamine, 25mM HEPES, 10% v/v FBS) and seeded at 1×10<sup>5</sup> cells per well in 10µL into Falcon 384-well plates (Corning). All ligand and vehicle solutions were prepared at 2× concentrations in the assay medium, and dispensed 10µL per well in 384-well plates at requisite time points. After equilibration in a humidified atmosphere at 37°C and 5% CO<sub>2</sub> for 1 h, cells were incubated with 10µM forskolin (canonical adenylyl cyclase activator, Tocris Bioscience) with or without stimulations of interest and/or vehicle (DMSO) controls. At the end of incubation, plates were rapidly cooled by placing on ice, and cells were lysed by adding 10µL per well of 3× concentrated ice-cold lysis buffer (formulation as per LANCE cAMP kit described below). The plates were placed on shakers at

500 RPM for 10 min at 4°C, and frozen at -80°C. The assays were performed without any phosphodiesterase inhibitors to allow for assessment of signaling kinetics.

cAMP detection was performed in ½-area white 96-well plates (PerkinElmer), using the LANCE cAMP Kit (PerkinElmer) with a high sensitivity method with 12µL per point lysate and total detection volume 24µL using 2× concentrated detection mix. Signal was detected on a CLARIOstar plate reader (BMG Labtech) using recommended TR-FRET settings. Assay sample cAMP concentrations were interpolated from standard curves. Data were normalized to vehicle (set as 0%) and forskolin (set as 100%) controls to allow compilation of data from independent experiments.

### ***ERK1/2 Phosphorylation Assay (p-ERK)***

PBMC were pelleted by centrifugation for 10 min at 250×g, re-suspended in assay medium, and seeded at 1×10<sup>5</sup> cells in 10µL per well into Falcon 384-well plates. Plates were incubated in a humidified atmosphere at 37°C and 5% CO<sub>2</sub> for 55 min, and then transferred to the surface of a water bath at 37°C and incubated for 5 min prior to adding ligands or vehicle controls. Treatments were prepared at 2× concentrations in assay medium, and dispensed 10µL per well at requisite time points. At the end of incubation, plates were placed on ice, and cells were lysed by addition of 10µL per well of 3× concentrated ice-cold lysis buffer (formulation as per AlphaLISA kit described below). The plates were placed on shakers (500 RPM, 10 min at 4°C) and frozen at -80°C. p-ERK detection was performed using the AlphaLISA SureFire Ultra p-ERK 1/2 (Thr202/Tyr204) Assay Kit (PerkinElmer) per the manufacturer's specifications in 1/2-area white 96-well plates. Signal was detected on a CLARIOstar plate reader with AlphaLISA-compatible filters. Counts were normalized to vehicle controls (100%) to allow compilation of data from independent experiments.

## ***Akt, p38, JNK, CREB Phosphorylation Assays***

PBMC were treated and lysed under the same conditions as described for the p-ERK assay. Analytes were detected using AlphaLISA SureFire Ultra p-Akt 1/2/3 (Ser473), p-JNK 1/2/3 (Thr183/Tyr185), p-p38 MAPK (Thr180/Tyr182), and p-CREB (Ser133) assay kits as described above.

## ***Application of G Protein Inhibitors***

In experiments with PTX (Sigma-Aldrich), cells were pelleted, re-suspended in the assay medium containing PTX 100 ng/mL or vehicle, and incubated for 5 h in a humidified atmosphere at 37°C and 5% CO<sub>2</sub>. After the incubation, the cells were counted and re-suspended in the same assay media with PTX or vehicle, equilibrated for 1 h as described for the signaling assays (bringing the total PTX incubation to 6 h), then ligands/vehicles added for signaling experiments. In gallein (Santa Cruz Biotechnology) or suramin derivatives NF023 (Abcam) and NF449 (Abcam) experiments, the inhibitors or their vehicles were added to cells at 10µM 30 min prior to adding ligands or vehicles. All ligand and vehicle solutions used in assays with inhibitors were prepared in assay media containing the inhibitors or vehicles, so that inhibitors or vehicle controls at 1× concentration were present for the entire duration of stimulations.

## ***Analysis of Cytokine Secretion***

PBMC were seeded at 4.5×10<sup>5</sup> cells per well in assay medium into 96 Well V-Bottom plates (Interlab), incubated for 30 min, if applicable pre-treated for 30 min with 1µM SR144528 (a kind gift from Roche Pharmaceuticals, Basel, Switzerland), 5µM WIN55212-3 (Tocris), 10µM G protein inhibitors (NF023, NF449, gallein), or vehicle control (DMSO), and subsequently treated with HU308 or vehicle, with or without forskolin and G protein inhibitors or antagonists if applicable, in 150µL final volume. After 12 h (multiplex screen) or 6 h (quantitative IL-6/IL-10

analysis) incubation in a humidified atmosphere at 37°C and 5% CO<sub>2</sub>, plates were centrifuged for 10 min at 250×g, and supernatants collected and frozen at -80°C. Remaining cell pellets were re-suspended and aliquots (in technical duplicate) diluted in Trypan blue for hemocytometer counting. Interleukins 2, 4, 6, 10, 12, 13, 17A, macrophage inflammatory protein (MIP-1α) and tumor necrosis factor (TNF-α) were detected using Cytometric Bead Array (CBA) technology (BD Biosciences) and assayed on an Accuri C6 flow cytometer (BD Biosciences) as described previously<sup>130</sup>. For the multiplex screen, two concentrations of standard in the lower and middle range of standard curves (78 and 625 pg/mL) were utilized as internal controls and the mean fluorescent intensity (MFI) of each cytokine was calculated. Concentrations of IL-6 and IL-10 were interpolated using FCAP Array software (v. 3.1, BD Biosciences) from standard curves. Manufacturer stated limits of detection (LOD) were 11.2, 1.4, 1.6, 0.13, 7.9, 0.6, 0.3, 0.2, and 1.2 pg/mL for interleukins 2, 4, 6, 10, 12, 13, 17A, MIP-1α, and TNF-α, respectively.

### **Data Analysis**

All analysis was performed in GraphPad Prism Software (v. 8.0; GraphPad Software Inc.). Data is presented as mean ± standard error of the mean (SEM) from three independent experiments performed in triplicate, each with samples from a separate subject (three subjects in total). Concentration-response curves were obtained by fitting three-parameter nonlinear regression curves. Normalized data were utilized for statistical analysis of selected experiments (figures 2D-E, 4B, 5B, as described in figure legends). Otherwise, statistical analyses were performed on raw data. Repeated measures designs were utilized to reflect that each independent experiment was carried out on a separate subject. Normal distribution and equality of variance were verified with Shapiro-Wilk and Brown-Forsythe tests. If these tests did not pass, a decimal logarithm transformation was performed which enabled adherence to parametric test

assumptions. If a statistically significant difference ( $p < 0.05$ ) was detected in one- or two-way ANOVA, data were further analyzed using either Holm–Šídák (for comparisons to control) or Tukey (when comparisons between multiple conditions were of interest) *post hoc* tests with significance levels indicated graphically as:  $p < 0.05$  (\*),  $p < 0.01$  (\*\*),  $p < 0.001$  (\*\*\*), *non-significant* (ns).

## Supporting Information

Pre-incubation with forskolin has no effect on net cAMP kinetics in human primary PBMC; stimulatory cAMP signaling is detectable without forskolin; effects of HU308 on cAMP and p-ERK responses in PBMC are concentration-dependent; SR144528 is selective for CB<sub>2</sub> over CB<sub>1</sub>; PBMC do not respond to a CB<sub>1</sub>-selective agonist ACEA in p-ERK assay; HU308 induces interleukins 6 and 10 but not IL-2, IL-4, IL-6, IL-10, IL-12, IL-13, IL-17A, MIP-1 $\alpha$  or TNF- $\alpha$  in PBMC; HU308 has no effect on cell concentrations after 6 or 12 h of incubation; cryopreservation of PBMC has no effect on CB<sub>2</sub> expression, nor p-ERK response.

## Acknowledgements

We thank John McGowan (University of Auckland, NZ) for synthesizing the ACEA. This research was supported by funding from the Auckland Medical Research Foundation and the Health Research Council NZ (to NG). YS was supported by Dean's International Doctoral Scholarship, Faculty of Medical and Health Sciences, The University of Auckland. The Accuri C6 flow cytometer was purchased with funding from the NZ Lottery Health Board (to ESG).

## References

- Galiegue, S., Mary, S., Marchand, J., Dussossoy, D., Carriere, D., Carayon, P., Bouaboula, M., Shire, D., Le Fur, G., and Casellas, P. (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. *Eur J Biochem* 232, 54–61. DOI: 10.1111/j.1432-1033.1995.tb20780.x.
- Gonsiorek, W., Hesk, D., Chen, S.-C., Kinsley, D., Fine, J. S., Jackson, J. V., Bober, L. A., Deno, G., Bian, H., Fossetta, J., Lunn, C. A., Kozlowski, J. A., Lavey, B., Piwinski, J., Narula, S. K., Lundell, D. J., and Hipkin, R. W. (2006) Characterization of peripheral human cannabinoid receptor (hCB2) expression and pharmacology using a novel radioligand, [<sup>35</sup>S]Sch225336. *J. Biol. Chem.* 281, 28143–51. DOI: 10.1074/jbc.M602364200.
- Pacher, P., and Kunos, G. (2013) Modulating the endocannabinoid system in human health and disease--successes and failures. *FEBS J.* 280, 1918–43. DOI: 10.1111/febs.12260.
- Bouaboula, M., Poinot-Chazel, C., Marchand, J., Canat, X., Bourrié, B., Rinaldi-Carmona, M., Calandra, B., Le Fur, G., and Casellas, P. (1996) Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. *Eur. J. Biochem.* 237, 704–11. DOI: 8647116.
- Soethoudt, M., Grether, U., Fingerle, J., Grim, T. W., Fezza, F., de Petrocellis, L., Ullmer, C., Rothenhäusler, B., Perret, C., van Gils, N., Finlay, D., MacDonald, C., Chicca, A., Gens, M. D., Stuart, J., de Vries, H., Mastrangelo, N., Xia, L., Alachouzos, G., Baggelaar, M. P., Martella, A., Mock, E. D., Deng, H., Heitman, L. H., Connor, M., Di Marzo, V., Gertsch, J., Lichtman, A. H., Maccarrone, M., Pacher, P., Glass, M., and van der Stelt, M. (2017) Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity. *Nat. Commun.* 8, 13958. DOI: 10.1038/ncomms13958.
- Brailoiu, G. C., Deliu, E., Marcu, J., Hoffman, N. E., Console-Bram, L., Zhao, P., Madesh, M., Abood, M. E., and Brailoiu, E. (2014) Differential activation of intracellular versus plasmalemmal CB2 Cannabinoid receptors. *Biochemistry* 53, 4990–4999. DOI: 10.1021/bi500632a.
- Rhee, M. H., Bayewitch, M., Avidor-Reiss, T., Levy, R., and Vogel, Z. (1998) Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. *J. Neurochem.* 71, 1525–1534. DOI: 10.1046/j.1471-4159.1998.71041525.x.
- Börner, C., Smida, M., Höllt, V., Schraven, B., and Kraus, J. (2009) Cannabinoid receptor type 1- and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling. *J. Biol. Chem.* 284, 35450–35460. DOI: 10.1074/jbc.M109.006338.
- Nogueras-Ortiz, C., Roman-Vendrell, C., Mateo-Semidey, G. E., Liao, Y.-H., Kendall, D. A., and Yudowski, G. A. (2017) Retromer stops beta-arrestin 1-mediated signaling from internalized cannabinoid 2 receptors. *Mol. Biol. Cell* 28, 3554–3561. DOI: 10.1091/mbc.e17-03-0198.
- Shoemaker, J. L., Ruckle, M. B., Mayeux, P. R., and Prather, P. L. (2005) Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. *J. Pharmacol. Exp. Ther.* 315, 828–38. DOI: 10.1124/jpet.105.089474.
- Correa, F., Mestre, L., Docagne, F., and Guaza, C. (2005) Activation of cannabinoid CB 2 receptor negatively regulates IL-12p40 production in murine macrophages: Role of IL-10 and ERK1/2 kinase signaling. *Br. J. Pharmacol.* 145, 441–448. DOI: 10.1038/sj.bjp.0706215.

12. Gertsch, J., Leonti, M., Raduner, S., Racz, I., Chen, J.-Z., Xie, X.-Q., Altmann, K.-H., Karsak, M., and Zimmer, A. (2008) Beta-caryophyllene is a dietary cannabinoid. *Proc. Natl. Acad. Sci. U. S. A.* 105, 9099–9104. DOI: 10.1073/pnas.0803601105.
13. Yamashita, M., Kimura, M., Kubo, M., Shimizu, C., Tada, T., Perlmutter, R. M., and Nakayama, T. (1999) T cell antigen receptor-mediated activation of the Ras/mitogen-activated protein kinase pathway controls interleukin 4 receptor function and type-2 helper T cell differentiation. *Proc. Natl. Acad. Sci.* 96, 1024–1029. DOI: 10.1073/pnas.96.3.1024.
14. Coopman, K., Smith, L. D., Wright, K. L., and Ward, S. G. (2007) Temporal variation in CB2R levels following T lymphocyte activation: Evidence that cannabinoids modulate CXCL12-induced chemotaxis. *Int. Immunopharmacol.* 7, 360–371. DOI: 10.1016/j.intimp.2006.11.008.
15. Nowell, P. C. (1960) Phytohemagglutinin: An Initiator of Mitosis in Cultures of Normal Human Leukocytes. *Cancer Res.* 20, 462–466.
16. Herrera, B., Carracedo, A., Diez-Zaera, M., Guzman, M., and Velasco, G. (2005) p38 MAPK is involved in CB2 receptor-induced apoptosis of human leukaemia cells. *FEBS Lett.* 579, 5084–5088. DOI: 10.1016/j.febslet.2005.08.021.
17. Gustafsson, K., Christensson, B., Sander, B., and Flygare, J. (2006) Cannabinoid receptor-mediated apoptosis induced by R(+)-methanandamide and Win55,212-2 is associated with ceramide accumulation and p38 activation in mantle cell lymphoma. *Mol. Pharmacol.* 70, 1612–20. DOI: 10.1124/mol.106.025981.
18. Do, Y., McKallip, R. J., Nagarkatti, M., and Nagarkatti, P. S. (2004) Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. *J. Immunol.* 173, 2373–2382. DOI: 10.1172/JCI2373 [pii].
19. Zhang, Y., Wang, X., Yang, H., Liu, H., Lu, Y., Han, L., and Liu, G. (2013) Kinase AKT controls innate immune cell development and function. *Immunology* 140, 143–152. DOI: 10.1111/imm.12123.
20. Gomez, O., Sanchez-Rodriguez, A., Le, M. Q. U., Sanchez-Caro, C., Molina-Holgado, F., and Molina-Holgado, E. (2011) Cannabinoid receptor agonists modulate oligodendrocyte differentiation by activating PI3K/Akt and the mammalian target of rapamycin (mTOR) pathways. *Br. J. Pharmacol.* 163, 1520–1532. DOI: 10.1111/bph.2011.163.
21. Utomo, W. K., Peppelenbosch, M. P., Braat, H., Parikh, K., de Vries, M., Fuhler, G. M., Comalada, M., Bruno, M. J., and van Goor, H. (2017) Modulation of Human Peripheral Blood Mononuclear Cell Signaling by Medicinal Cannabinoids. *Front. Mol. Neurosci.* 10, 1–11. DOI: 10.3389/fnmol.2017.00014.
22. Gómez del Pulgar, T., Velasco, G., and Guzmán, M. (2000) The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. *Biochem. J.* 347, 369–73. DOI: 10.1124/mol.58.4.814.
23. Kim, E. K., and Choi, E.-J. (2010) Pathological roles of MAPK signaling pathways in human diseases. *Biochim. Biophys. Acta* 1802, 396–405. DOI: 10.1016/j.bbadis.2009.12.009.
24. Li, A.-L., Lin, X., Dhopeswarkar, A. S., Thomaz, A. C., Carey, L. M., Liu, Y., Nikas, S. P., Makriyannis, A., Mackie, K., and Hohmann, A. G. (2019) Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal. *Mol. Pharmacol.* 95, 155–168. DOI: 10.1124/mol.118.113233.

25. Sugiura, T., Kishimoto, S., Oka, S., Gokoh, M., and Waku, K. (2004) Metabolism and physiological significance of anandamide and 2-arachidonoylglycerol, endogenous cannabinoid receptor ligands, in *Arachidonate Remodeling and Inflammation* (Fonteh, A. N., and Wykle, R. L., Eds.), pp 211–237. Birkhäuser Basel, Basel. DOI: 10.1007/978-3-0348-7848-7\_11.
26. Rom, S., and Persidsky, Y. (2013) Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation. *J. Neuroimmune Pharmacol.* 8, 608–20. DOI: 10.1007/s11481-013-9445-9.
27. Ihenetu, K., Molleman, A., Parsons, M., and Whelan, C. (2003) Pharmacological characterisation of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells. *Eur. J. Pharmacol.* 464, 207–15. DOI: 10.1016/s0014-2999(03)01379-7.
28. Cencioni, M. T., Chiurchiù, V., Catanzaro, G., Borsellino, G., Bernardi, G., Battistini, L., and Maccarrone, M. (2010) Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. *PLoS One* 5, e8688. DOI: 10.1371/journal.pone.0008688.
29. Yuan, M., Kiertscher, S. M., Cheng, Q., Zoumalan, R., Tashkin, D. P., and Roth, M. D. (2002) Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. *J. Neuroimmunol.* 133, 124–31. DOI: 10.1016/S0165-5728(02)00370-3.
30. Gardner, B., Zu, L. X., Sharma, S., Liu, Q., Makriyannis, A., Tashkin, D. P., and Dubinett, S. M. (2002) Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-beta. *Biochem. Biophys. Res. Commun.* 290, 91–6. DOI: 10.1006/bbrc.2001.6179.
31. Massi, P., Sacerdote, P., Ponti, W., Fuzio, D., Manfredi, B., Viganó, D., Rubino, T., Bardotti, M., and Parolaro, D. (1998) Immune function alterations in mice tolerant to Δ9-tetrahydrocannabinol: Functional and biochemical parameters. *J. Neuroimmunol.* 92, 60–66. DOI: 10.1016/S0165-5728(98)00177-5.
32. Newton, C. A., Klein, T. W., and Friedman, H. (1994) Secondary immunity to *Legionella pneumophila* and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection. *Infect. Immun.* 62, 4015–4020. DOI: 10.1016/j.otsr.2014.03.018.
33. Klein, T. W., Newton, C. A., Nakachi, N., and Friedman, H. (2000) 9-Tetrahydrocannabinol Treatment Suppresses Immunity and Early IFN-gamma, IL-12, and IL-12 Receptor 2 Responses to *Legionella pneumophila* Infection. *J. Immunol.* 164, 6461–6466. DOI: 10.4049/jimmunol.164.12.6461.
34. Nakano, Y., Pross, S., and Friedman, H. (1993) Contrasting effect of delta-9-tetrahydrocannabinol on IL-2 activity in spleen and lymph node cells of mice of different ages. *Life Sci.* 52, 41–51. DOI: 10.1016/0024-3205(93)90287-d.
35. Hillard, C. J., Manna, S., Greenberg, M. J., DiCamelli, R., Ross, R. A., Stevenson, L. A., Murphy, V., Pertwee, R. G., and Campbell, W. B. (1999) Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). *J. Pharmacol. Exp. Ther.* 289, 1427–33. DOI: 10.1093/bioinformatics/btv135.
36. Hanus, L., Breuer, A., Tchilibon, S., Shiloah, S., Goldenberg, D., Horowitz, M., Pertwee, R. G., Ross, R. A., Mechoulam, R., and Fride, E. (1999) HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. *Proc. Natl. Acad. Sci. U. S. A.* 96, 14228–33. DOI: 10.1073/pnas.96.25.14228.

37. Oyagawa, C. R. M., de la Harpe, S. M., Saroz, Y., Glass, M., Vernall, A. J., and Grimsey, N. L. (2018) Cannabinoid Receptor 2 Signalling Bias Elicited by 2,4,6-Trisubstituted 1,3,5-Triazines. *Front. Pharmacol.* 9, 1202. DOI: 10.3389/fphar.2018.01202.
38. Locht, C., and Antoine, R. (1995) A proposed mechanism of ADP-ribosylation catalyzed by the pertussis toxin S1 subunit. *Biochimie* 77, 333–340. DOI: 10.1016/0300-9084(96)88143-0.
39. Milligan, G., and Kostenis, E. (2006) Heterotrimeric G-proteins: A short history. *Br. J. Pharmacol.* 147. DOI: 10.1038/sj.bjp.0706405.
40. Hohenegger, M., Waldhoer, M., Beindl, W., Bing, B., Kreimeyer, A., Nickel, P., Nanoff, C., Freissmuth, A. M., and Gilman, A. G. (1998) Gs alpha-selective G protein antagonists. *Pharmacology* 95, 346–351. DOI: 10.1073/pnas.95.1.346.
41. Dhopeshwarkar, A., and Mackie, K. (2016) Functional selectivity of CB2 cannabinoid receptor ligands at a canonical and non-canonical pathway. *J. Pharmacol. Exp. Ther.* 358, 342–351. DOI: 10.1124/jpet.116.232561.
42. Freissmuth, M., Boehm, S., Beindl, W., Nickel, P., Ijzerman, A. P., Hohenegger, M., and Nanoff, C. (1996) Suramin analogues as subtype-selective G protein inhibitors. *Mol. Pharmacol.* 49, 602–11.
43. Lehmann, D. M., Seneviratne, A. M. P. B., and Smrcka, A. V. (2007) Small Molecule Disruption of G Protein Subunit Signaling Inhibits Neutrophil Chemotaxis and Inflammation. *Mol. Pharmacol.* 73, 410–418. DOI: 10.1124/mol.107.041780.
44. Rinaldi-Carmona, M., Barth, F., Millan, J., Derocq, J. M., Casellas, P., Congy, C., Oustric, D., Sarran, M., Bouaboula, M., Calandra, B., Portier, M., Shire, D., Breliere, J. C., and Le Fur, G. L. (1998) SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. *J. Pharmacol. Exp. Ther.* 284, 644–650.
45. Savinainen, J. R., Kokkola, T., Salo, O. M. H., Poso, A., Järvinen, T., and Laitinen, J. T. (2005) Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB 2 receptor. *Br. J. Pharmacol.* 145, 636–645. DOI: 10.1038/sj.bjp.0706230.
46. Sugiura, T., Kondo, S., Miyashita, T., Kodaka, T., Suhara, Y., Takayama, H., and Waku, K. (2000) Evidence That 2-Arachidonoylglycerol but Not N -Palmitoylethanolamine or Anandamide Is the Physiological Ligand for the Cannabinoid CB2 Receptor. *J. Biol. Chem.* 275, 605–12.
47. Arkun, Y., and Yasemi, M. (2018) Dynamics and control of the ERK signaling pathway: Sensitivity, bistability, and oscillations. *PLoS One* (Thattai, M., Ed.) 13, e0195513. DOI: 10.1371/journal.pone.0195513.
48. Compagnucci, C., Di Siena, S., Bustamante, M. B., Di Giacomo, D., Di Tommaso, M., Maccarrone, M., Grimaldi, P., and Sette, C. (2013) Type-1 (CB1) Cannabinoid Receptor Promotes Neuronal Differentiation and Maturation of Neural Stem Cells. *PLoS One* (Androutsellis-Theotokis, A., Ed.) 8, e54271. DOI: 10.1371/journal.pone.0054271.
49. Johannessen, M., Delghandi, M. P., and Moens, U. (2004) What turns CREB on? *Cell. Signal.* 16, 1211–1227. DOI: 10.1016/j.cellsig.2004.05.001.
50. Finlay, D. B., Cawston, E. E., Grimsey, N. L., Hunter, M. R., Korde, A., Vemuri, V. K., Makriyannis, A., and Glass, M. (2017) Gαs signalling of the CB1 receptor and the influence of receptor number. *Br. J. Pharmacol.* 174, 2545–2562. DOI: 10.1111/bph.13866.
51. Felder, C. C., Joyce, K. E., Briley, E. M., Mansouri, J., Mackie, K., Blond, O., Lai, Y., Ma,

- A. L., and Mitchell, R. L. (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. *Mol. Pharmacol.* **48**, 443–50.
52. Slipetz, D. M., O'Neill, G. P., Favreau, L., Dufresne, C., Gallant, M., Gareau, Y., Guay, D., Labelle, M., and Metters, K. M. (1995) Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. *Mol. Pharmacol.* **48**, 352–361.
53. Scherzer, J. A., Lin, Y., McLeish, K. R., and Klein, J. B. (1997) TNF translationally modulates the expression of G1 protein alpha(i2) subunits in human polymorphonuclear leukocytes. *J Immunol* **158**, 913–918.
54. Kuwano, Y., Adler, M., Zhang, H., Groisman, A., and Ley, K. (2016) Gai2 and Gai3 Differentially Regulate Arrest from Flow and Chemotaxis in Mouse Neutrophils. *J. Immunol.* **196**, 3828–3833. DOI: 10.4049/jimmunol.1500532.
55. Duan, B., Davis, R., Sadat, E. L., Collins, J., Sternweis, P. C., Yuan, D., and Jiang, L. I. (2010) Distinct Roles of Adenylyl Cyclase VII in Regulating the Immune Responses in Mice. *J. Immunol.* **185**, 335–344. DOI: 10.4049/jimmunol.0903474.
56. Leander, R., and Friedman, A. (2014) Modulation of the cAMP Response by G alpha i and G beta gamma: A Computational Study of G Protein Signaling in Immune Cells. *Bull. Math. Biol.* **76**, 1352–1375. DOI: 10.1007/s11538-014-9964-4.
57. Glass, M., and Felder, C. C. (1997) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. *J. Neurosci.* **17**, 5327–33.
58. Navarro, G., Reyes-Resina, I., Rivas-Santisteban, R., Sánchez de Medina, V., Morales, P., Casano, S., Ferreira-Vera, C., Lillo, A., Aguinaga, D., Jagerovic, N., Nadal, X., and Franco, R. (2018) Cannabidiol skews biased agonism at cannabinoid CB1 and CB2 receptors with smaller effect in CB1-CB2 heteroreceptor complexes. *Biochem. Pharmacol.* **157**, 148–158. DOI: 10.1016/j.bcp.2018.08.046.
59. Ferré, S. (2015) The GPCR heterotetramer: challenging classical pharmacology. *Trends Pharmacol. Sci.* **36**, 145–52. DOI: 10.1016/j.tips.2015.01.002.
60. Ellisdon, A. M., and Halls, M. L. (2016) Compartmentalization of GPCR signalling controls unique cellular responses. *Biochem. Soc. Trans.* **44**, 562–7. DOI: 10.1042/BST20150236.
61. Kleyer, J., Nicolussi, S., Taylor, P., Simonelli, D., Furger, E., Anderle, P., and Gertsch, J. (2012) Cannabinoid receptor trafficking in peripheral cells is dynamically regulated by a binary biochemical switch. *Biochem. Pharmacol.* **83**, 1393–1412. DOI: 10.1016/j.bcp.2012.02.014.
62. Castaneda, J. T., Harui, A., Kiertscher, S. M., Roth, J. D., and Roth, M. D. (2013) Differential Expression of Intracellular and Extracellular CB 2 Cannabinoid Receptor Protein by Human Peripheral Blood Leukocytes 2, 323–332. DOI: 10.1007/s11481-012-9430-8.
63. Castaneda, J. T., Harui, A., and Roth, M. D. (2017) Regulation of Cell Surface CB2 Receptor during Human B Cell Activation and Differentiation. *J. Neuroimmune Pharmacol.* **12**, 544–554. DOI: 10.1007/s11481-017-9744-7.
64. Daaka, Y., Luttrell, L. M., and Lefkowitz, R. J. (1997) Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. *Nature* **390**, 88–91. DOI: 10.1038/36362.
65. Tesmer, V. M., Kawano, T., Shankaranarayanan, A., Kozasa, T., and Tesmer, J. J. G. (2005) Snapshot of activated G proteins at the membrane: the Galphaq-GRK2-Gbetagamma complex. *Science* **310**, 1686–90. DOI: 10.1126/science.1118890.

66. Zhu, W., Petrashevskaya, N., Ren, S., Zhao, A., Chakir, K., Gao, E., Chuprun, J. K., Wang, Y., Talan, M., Dorn, G. W., Lakatta, E. G., Koch, W. J., Feldman, A. M., and Xiao, R.-P. (2012) Gi-biased  $\beta$ 2AR signaling links GRK2 upregulation to heart failure. *Circ. Res.* 110, 265–74. DOI: 10.1161/CIRCRESAHA.111.253260.
67. Olinas, M. C., Ingianni, A., and Onali, P. (1998) Role of G protein betagamma subunits in muscarinic receptor-induced stimulation and inhibition of adenylyl cyclase activity in rat olfactory bulb. *J. Neurochem.* 70, 2620–7. DOI: 10.1046/j.1471-4159.1998.70062620.x.
68. Uezono, Y., Kaibara, M., Murasaki, O., and Taniyama, K. (2004) Involvement of G protein betagamma-subunits in diverse signaling induced by G(i/o)-coupled receptors: study using the *Xenopus* oocyte expression system. *Am. J. Physiol. Cell Physiol.* 287, C885-94. DOI: 10.1152/ajpcell.00125.2004.
69. Conti, M., Mika, D., and Richter, W. (2014) Cyclic AMP compartments and signaling specificity: role of cyclic nucleotide phosphodiesterases. *J. Gen. Physiol.* 143, 29–38. DOI: 10.1085/jgp.201311083.
70. Roskoski, R. (2012) ERK1/2 MAP kinases: Structure, function, and regulation. *Pharmacol. Res.* 66, 105–143. DOI: 10.1016/j.phrs.2012.04.005.
71. Agrawal, A., Dillon, S., Denning, T. L., and Pulendran, B. (2006) ERK1-/- Mice Exhibit Th1 Cell Polarization and Increased Susceptibility to Experimental Autoimmune Encephalomyelitis. *J. Immunol.* 176, 5788–5796. DOI: 10.1093/imm.176.10.5788 [pii].
72. Dumitru, C. D., Ceci, J. D., Tsatsanis, C., Kontoyiannis, D., Stamatakis, K., Lin, J. H., Patriotis, C., Jenkins, N. A., Copeland, N. G., Kollias, G., and Tschlis, P. N. (2000) TNF- $\alpha$  induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. *Cell* 103, 1071–1083. DOI: 10.1016/S0092-8674(00)00210-5.
73. Kamal, F. A., Travers, J. G., Schafer, A. E., Ma, Q., Devarajan, P., and Blaxall, B. C. (2016) G Protein–Coupled Receptor-G–Protein  $\beta\gamma$  –Subunit Signaling Mediates Renal Dysfunction and Fibrosis in Heart Failure. *J. Am. Soc. Nephrol.* 28, 197–208. DOI: 10.1681/asn.2015080852.
74. van Der Lee, M. M. C., Bras, M., van Koppen, C. J., and Zaman, G. J. R. (2008) beta-Arrestin recruitment assay for the identification of agonists of the sphingosine 1-phosphate receptor EDG1. *J. Biomol. Screen.* 13, 986–98. DOI: 10.1177/1087057108326144.
75. Saitoh, F., Wakatsuki, S., Tokunaga, S., Fujieda, H., and Araki, T. (2016) Glutamate signals through mGluR2 to control Schwann cell differentiation and proliferation. *Sci. Rep.* 6, 1–14. DOI: 10.1038/srep29856.
76. Simo-Cheyrou, E. R., Vardatsikos, G., and Srivastava, A. K. (2016) Src tyrosine kinase mediates endothelin-1-induced early growth response protein-1 expression via MAP kinase-dependent pathways in vascular smooth muscle cells. *Int. J. Mol. Med.* 38, 1879–1886. DOI: 10.3892/ijmm.2016.2767.
77. Dhopeswarkar, A., and Mackie, K. (2014) CB2 Cannabinoid receptors as a therapeutic target-what does the future hold? *Mol. Pharmacol.* 86, 430–7. DOI: 10.1124/mol.114.094649.
78. Graham, E. S., Ball, N., Scotter, E. L., Narayan, P., Dragunow, M., and Glass, M. (2006) Induction of Krox-24 by Endogenous Cannabinoid Type 1 Receptors in Neuro2A Cells Is Mediated by the MEK-ERK MAPK Pathway and Is Suppressed by the Phosphatidylinositol 3-Kinase Pathway. *J. Biol. Chem.* 281, 29085–29095. DOI: 10.1074/jbc.M602516200.
79. Gurevich, V. V., and Gurevich, E. V. (2018) Arrestins and G proteins in cellular signaling:

The coin has two sides. *Sci. Signal.* **11**, eaav1646. DOI: 10.1126/scisignal.aav1646.

80. Marazzi, J., Kleyer, J., Paredes, J. M. V., and Gertsch, J. (2011) Endocannabinoid content in fetal bovine sera — Unexpected effects on mononuclear cells and osteoclastogenesis. *J. Immunol. Methods* **373**, 219–228. DOI: 10.1016/j.jim.2011.08.021.

81. Park, J. M., Greten, F. R., Wong, A., Westrick, R. J., Arthur, J. S. C., Otsu, K., Hoffmann, A., Montminy, M., and Karin, M. (2005) Signaling Pathways and Genes that Inhibit Pathogen-Induced Macrophage Apoptosis— CREB and NF- $\kappa$ B as Key Regulators. *Immunity* **23**, 319–329. DOI: 10.1016/j.immuni.2005.08.010.

82. Yu, C.-T., Shih, H. -m., and Lai, M.-Z. (2001) Multiple Signals Required for Cyclic AMP-Responsive Element Binding Protein (CREB) Binding Protein Interaction Induced by CD3/CD28 Costimulation. *J. Immunol.* **166**, 284–292. DOI: 10.4049/jimmunol.166.1.284.

83. Grady, G. C., Mason, S. M., Stephen, J., Zuniga-Pflucker, J. C., and Michie, A. M. (2004) Cyclic Adenosine 5'-Monophosphate Response Element Binding Protein Plays a Central Role in Mediating Proliferation and Differentiation Downstream of the Pre-TCR Complex in Developing Thymocytes. *J. Immunol.* **173**, 1802–1810. DOI: 10.4049/jimmunol.173.3.1802.

84. Yasuda, T., Sanjo, H., Pagès, G., Kawano, Y., Karasuyama, H., Pouyssegur, J., Ogata, M., and Kurosaki, T. (2008) Erk Kinases Link Pre-B Cell Receptor Signaling to Transcriptional Events Required for Early B Cell Expansion. *Immunity* **28**, 499–508. DOI: 10.1016/j.immuni.2008.02.015.

85. Bomsel, M., and Mostov, K. E. (1993) Possible role of both the alpha and beta gamma subunits of the heterotrimeric G protein, Gs, in transcytosis of the polymeric immunoglobulin receptor. *J. Biol. Chem.* **268**, 25824–35.

86. McIntire, W. E., MacCleery, G., and Garrison, J. C. (2001) The G protein beta subunit is a determinant in the coupling of Gs to the beta 1-adrenergic and A2a adenosine receptors. *J. Biol. Chem.* **276**, 15801–9. DOI: 10.1074/jbc.M011233200.

87. Wen, A. Y., Sakamoto, K. M., and Miller, L. S. (2010) The Role of the Transcription Factor CREB in Immune Function. *J. Immunol.* **185**, 6413–6419. DOI: 10.4049/jimmunol.1001829.

88. Baló-Banga, J. M., Schweitzer, K., Lakatos, S., and Sipka, S. (2015) A novel rapid (20-minute) IL-6 release assay using blood mononuclear cells of patients with various clinical forms of drug induced skin injuries. *World Allergy Organ. J.* **8**, 1. DOI: 10.1186/1939-4551-8-1.

89. McHugh, S. M., Wilson, A. B., Deighton, J., Lachmann, P. J., and Ewan, P. W. (1994) The profiles of interleukin (IL)-2, IL-6, and interferon-gamma production by peripheral blood mononuclear cells from house-dust-mite-allergic patients: a role for IL-6 in allergic disease. *Allergy* **49**, 751–9. DOI: 10.1111/j.1398-9995.1994.tb02098.x.

90. Fan, J., Nishanian, P., Breen, E. C., McDonald, M., and Fahey, J. L. (1998) Cytokine gene expression in normal human lymphocytes in response to stimulation. *Clin. Diagn. Lab. Immunol.* **5**, 335–40.

91. Breen, E. C., McDonald, M., Fan, J., Boscardin, J., and Fahey, J. L. (2000) Cytokine gene expression occurs more rapidly in stimulated peripheral blood mononuclear cells from human immunodeficiency virus-infected persons. *Clin. Diagn. Lab. Immunol.* **7**, 769–73. DOI: 10.1128/cdli.7.5.769-773.2000.

92. Wysk, M., Yang, D. D., Lu, H. T., Flavell, R. A., and Davis, R. J. (1999) Requirement of mitogen-activated protein kinase kinase 3 (MKK3) for tumor necrosis factor-induced cytokine

expression. *Proc. Natl. Acad. Sci. U. S. A.* 96, 3763–8. DOI: 10.1073/pnas.96.7.3763.

93. Mortaz, E., Lazar, Z., Koenderman, L., Kraneveld, A. D., Nijkamp, F. P., and Folkerts, G. (2009) Cigarette smoke attenuates the production of cytokines by human plasmacytoid dendritic cells and enhances the release of IL-8 in response to TLR-9 stimulation. *Respir. Res.* 10, 47. DOI: 10.1186/1465-9921-10-47.

94. Horie, K., Ohashi, M., Satoh, Y., and Sairenji, T. (2007) The role of p38 mitogen-activated protein kinase in regulating interleukin-10 gene expression in Burkitt's lymphoma cell lines. *Microbiol. Immunol.* 51, 149–161. DOI: 10.1111/j.1348-0421.2007.tb03885.x.

95. Pengal, R. A., Ganesan, L. P., Wei, G., Fang, H., Ostrowski, M. C., and Tridandapani, S. (2006) Lipopolysaccharide-induced production of interleukin-10 is promoted by the serine/threonine kinase Akt. *Mol. Immunol.* 43, 1557–1564. DOI: 10.1016/j.molimm.2005.09.022.

96. Morrison, D. C., and Ulevitch, R. J. (1978) The effects of bacterial endotoxins on host mediation systems. A review. *Am. J. Pathol.* 93, 526–618.

97. Galve-Roperh, I., Sánchez, C., Cortés, M. L., Gómez del Pulgar, T., Izquierdo, M., and Guzmán, M. (2000) Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. *Nat. Med.* 6, 313–9. DOI: 10.1038/73171.

98. Sánchez, C., de Ceballos, M. L., Gomez del Pulgar, T., Rueda, D., Corbacho, C., Velasco, G., Galve-Roperh, I., Huffman, J. W., Ramón y Cajal, S., and Guzmán, M. (2001) Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. *Cancer Res.* 61, 5784–9.

99. Cridge, B. J., and Rosengren, R. J. (2013) Critical appraisal of the potential use of cannabinoids in cancer management. *Cancer Manag. Res.* 5, 301–13. DOI: 10.2147/CMAR.S36105.

100. Maccarrone, M., Lorenzon, T., Bari, M., Melino, G., and Finazzi-Agro, A. (2000) Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. *J. Biol. Chem.* 275, 31938–31945. DOI: 10.1074/jbc.M005722200.

101. Joss, A., Akdis, M., Faith, A., Blaser, K., and Akdis, C. A. (2000) IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway. *Eur. J. Immunol.* 30, 1683–90. DOI: 10.1002/1521-4141(200006)30:6<1683::AID-IMMU1683>3.0.CO;2-A.

102. Fiorentino, D. F., Zlotnik, A., Mosmann, T. R., Howard, M., and O'Garra, A. (1991) IL-10 inhibits cytokine production by activated macrophages. *J. Immunol.* 147, 3815–22.

103. Corinti, S., Albanesi, C., la Sala, A., Pastore, S., and Girolomoni, G. (2001) Regulatory activity of autocrine IL-10 on dendritic cell functions. *J. Immunol.* 166, 4312–8. DOI: 10.4049/jimmunol.166.7.4312.

104. Schett, G. (2018) Physiological effects of modulating the interleukin-6 axis. *Rheumatology* 57, ii43–ii50. DOI: 10.1093/rheumatology/kex513.

105. Janský, L., Reymanová, P., and Kopecký, J. (2003) Dynamics of cytokine production in human peripheral blood mononuclear cells stimulated by LPS or infected by *Borrelia*. *Physiol. Res.* 52, 593–8.

106. McGeachy, M. J., Bak-Jensen, K. S., Chen, Y., Tato, C. M., Blumenschein, W., McClanahan, T., and Cua, D. J. (2007) TGF- $\beta$  and IL-6 drive the production of IL-17 and IL-10

- by T cells and restrain TH-17 cell-mediated pathology. *Nat. Immunol.* 8, 1390–1397. DOI: 10.1038/ni1539.
107. Jin, J.-O., Han, X., and Yu, Q. (2013) Interleukin-6 induces the generation of IL-10-producing Tr1 cells and suppresses autoimmune tissue inflammation. *J. Autoimmun.* 40, 28–44. DOI: 10.1016/j.jaut.2012.07.009.
108. Steensberg, A., Fischer, C. P., Keller, C., Møller, K., and Pedersen, B. K. (2003) IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. *Am. J. Physiol. - Endocrinol. Metab.* 285, E433–E437. DOI: 10.1152/ajpendo.00074.2003.
109. Lee, S., Lee, T. A., Lee, E., Kang, S., Park, A., Kim, S. W., Park, H. J., Yoon, J. H., Ha, S. J., Park, T., Lee, J. S., Cheon, J. H., and Park, B. (2015) Identification of a subnuclear body involved in sequence-specific cytokine RNA processing. *Nat. Commun.* 6, 1–14. DOI: 10.1038/ncomms6791.
110. Fiorentino, D. F., Bond, M. W., and Mosmann, T. R. (1989) Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. *J. Exp. Med.* 170, 2081–95. DOI: 10.1084/jem.170.6.2081.
111. Mosmann, T. R., and Sad, S. (1996) The expanding universe of T-cell subsets: Th1, Th2 and more. *Immunol. Today* 17, 138–46. DOI: 10.1016/0167-5699(96)80606-2.
112. Schuerwegh, A. J., De Clerck, L. S., Bridts, C. H., and Stevens, W. J. (2003) Comparison of intracellular cytokine production with extracellular cytokine levels using two flow cytometric techniques. *Cytometry* 55B, 52–58. DOI: 10.1002/cyto.b.10041.
113. Jang, S., Uematsu, S., Akira, S., and Salgame, P. (2004) IL-6 and IL-10 induction from dendritic cells in response to Mycobacterium tuberculosis is predominantly dependent on TLR2-mediated recognition. *J. Immunol.* 173, 3392–7. DOI: 10.4049/jimmunol.173.5.3392.
114. Qu, Q.-X., Xie, F., Huang, Q., and Zhang, X.-G. (2017) Membranous and Cytoplasmic Expression of PD-L1 in Ovarian Cancer Cells. *Cell. Physiol. Biochem.* 43, 1893–1906. DOI: 10.1159/000484109.
115. Raduner, S., Majewska, A., Chen, J.-Z., Xie, X.-Q., Hamon, J., Faller, B., Altmann, K.-H., and Gertsch, J. (2006) Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. *J. Biol. Chem.* 281, 14192–206. DOI: 10.1074/jbc.M601074200.
116. Zhu, L. X., Sharma, S., Stolina, M., Gardner, B., Roth, M. D., Tashkin, D. P., and Dubinett, S. M. (2000) Delta-9-Tetrahydrocannabinol Inhibits Antitumor Immunity by a CB2 Receptor-Mediated, Cytokine-Dependent Pathway. *J. Immunol.* 165, 373–380. DOI: 10.4049/jimmunol.165.1.373.
117. Kozela, E., Juknat, A., Kaushansky, N., Rimmerman, N., Ben-Nun, A., and Vogel, Z. (2013) Cannabinoids Decrease the Th17 Inflammatory Autoimmune Phenotype. *J. Neuroimmune Pharmacol.* 8, 1265–1276. DOI: 10.1007/s11481-013-9493-1.
118. Massi, P., Vaccani, A., and Parolaro, D. (2006) Cannabinoids, immune system and cytokine network. *Curr. Pharm. Des.* 12, 3135–46. DOI: 10.2174/138161206777947425.
119. Eisenstein, T. K., and Meissler, J. J. (2015) Effects of Cannabinoids on T-cell Function and Resistance to Infection. *J. Neuroimmune Pharmacol.* 10, 204–16. DOI: 10.1007/s11481-015-9603-3.
120. Pacifici, R., Zuccaro, P., Pichini, S., Roset, P. N., Poudevida, S., Farré, M., Segura, J., and De la Torre, R. (2003) Modulation of the immune system in cannabis users. *JAMA* 289,

1929–31. DOI: 10.1001/jama.289.15.1929-b.

121. Bayazit, H., Selek, S., Karababa, I. F., Cicek, E., and Aksoy, N. (2017) Evaluation of oxidant/antioxidant status and cytokine levels in patients with cannabis use disorder. *Clin. Psychopharmacol. Neurosci.* 15, 237–242. DOI: 10.9758/cpn.2017.15.3.237.

122. Katona, S., Kaminski, E., Sanders, H., and Zajicek, J. (2005) Cannabinoid influence on cytokine profile in multiple sclerosis. *Clin. Exp. Immunol.* 140, 580–5. DOI: 10.1111/j.1365-2249.2005.02803.x.

123. Cannaert, A., Storme, J., Franz, F., Auwärter, V., and Stove, C. P. (2016) Detection and Activity Profiling of Synthetic Cannabinoids and Their Metabolites with a Newly Developed Bioassay. *Anal. Chem.* 88, 11476–11485. DOI: 10.1021/acs.analchem.6b02600.

124. Doi, T., Tagami, T., Takeda, A., Asada, A., and Sawabe, Y. (2018) Evaluation of carboxamide-type synthetic cannabinoids as CB1/CB2 receptor agonists: difference between the enantiomers. *Forensic Toxicol.* 36, 51–60. DOI: 10.1007/s11419-017-0378-5.

125. Riley, S. B., Sochat, M., Moser, K., Lynch, K. L., Tochtrop, R., Isbell, T. S., and Scalzo, A. (2019) Case of brodifacoum-contaminated synthetic cannabinoid. *Clin. Toxicol. (Phila).* 57, 143–144. DOI: 10.1080/15563650.2018.1502444.

126. Cawston, E. E., Redmond, W. J., Breen, C. M., Grimsey, N. L., Connor, M., and Glass, M. (2013) Real-time characterization of cannabinoid receptor 1 (CB1) allosteric modulators reveals novel mechanism of action. *Br. J. Pharmacol.* 170, 893–907. DOI: 10.1111/bph.12329.

127. Lin, S., Khanolkar, A. D., Fan, P., Goutopoulos, A., Qin, C., Papahadjis, D., and Makriyannis, A. (1998) Novel analogues of arachidonylethanolamide (anandamide): Affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. *J. Med. Chem.* 41, 5353–5361. DOI: 10.1021/jm970257g.

128. Hulme, E. C., and Trevethick, M. A. (2010) Ligand binding assays at equilibrium: Validation and interpretation. *Br. J. Pharmacol.* 161, 1219–1237. DOI: 10.1111/j.1476-5381.2009.00604.x.

129. Motulsky, H. J., and Neubig, R. R. (2010) Analyzing binding data. *Curr. Protoc. Neurosci.* Chapter 7, Unit 7.5. DOI: 10.1002/0471142301.ns0705s52.

130. O'Carroll, S. J., Kho, D. T., Wiltshire, R., Nelson, V., Rotimi, O., Johnson, R., Angel, C. E., and Graham, E. S. (2015) Pro-inflammatory TNF $\alpha$  and IL-1 $\beta$  differentially regulate the inflammatory phenotype of brain microvascular endothelial cells. *J. Neuroinflammation* 12, 1–18. DOI: 10.1186/s12974-015-0346-0.